tocilizumab + methotrexate + simvastatin

A combination of **tocilizumab** (a monoclonal antibody that inhibits interleukin-6 receptor), **methotrexate** (an antimetabolite and antifolate that inhibits dihydrofolate reductase), and **simvastatin** (an HMG-CoA reductase inhibitor/statin). This combination has been clinically studied specifically to evaluate potential pharmacokinetic and pharmacodynamic drug interactions, particularly in patients with rheumatoid arthritis[1][3][7]. While tocilizumab and methotrexate are frequently used together in RA therapy to prevent disease progression and inflammation, simvastatin is sometimes used for cardiovascular comorbidity management. Tocilizumab primarily blocks IL-6 mediated signaling, methotrexate acts as an anti-inflammatory by inhibiting folate metabolism, and simvastatin reduces cholesterol synthesis by inhibiting the enzyme HMG-CoA reductase.